Loading stock data…
AKTS
$19.44+0.44 (+2.32%)
Pre-Market$19.16-0.28 (-1.44%)· Last close May 5
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.44
Potential Upside
5%
Whystock Fair Value$20.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-11...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.61%
Volume
Today's trading volume
115,911
Recent News
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate indication-specific data in metastatic castration-resistant prostate cancer (mCRPC) while also exploring broader po
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump
Key recent performance snapshot Aktis Oncology (AKTS) has drawn investor attention after a recent one-month return of about 40%, contrasting with a small decline over the past three months and a modest year-to-date loss. The clinical-stage company, focused on targeted radiopharmaceuticals for solid tumors, currently has a market value of about US$1.18 billion and last closed at US$21.26 per share. See our latest analysis for Aktis Oncology. For context, the recent 40% 1 month share price...
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33
Aktis Oncology, Inc. (NASDAQ:AKTS) is one of the 8 Healthcare Stocks Insiders Are Buying. On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintained a Buy rating on the shares. Robert Burns has said that the company’s pipeline is […]
Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs
Aktis Oncology (NASDAQ:AKTS) executives outlined the company’s strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel “miniprotein” targeting approach, internally built supply chain capabilities, and two lead clinical pr